"positive breast cancer" trang 3 - tải miễn phí từ tailieunhanh
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99
9    49    1
ERβ1: Characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer

ERβ1: Characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer
16    70    1
Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
9    58    1
Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma
11    30    1
Investigation of exon20 PIK3CA gene mutation in plasma of hormone receptor positive breast cancer patients

Investigation of exon20 PIK3CA gene mutation in plasma of hormone receptor positive breast cancer patients
9    1    1
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
7    39    1
Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer

Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer
9    40    1
Predictors of breast cancer cell types and their prognostic power in breast cancer patients

Predictors of breast cancer cell types and their prognostic power in breast cancer patients
13    31    1
Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway

Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway
14    97    1
Breast cancer with scalp metastases: A case report

Breast cancer with scalp metastases: A case report
7    19    1
Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells

Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells
17    48    1
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: An international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)

Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: An international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)
10    1    1
MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
14    29    1
Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2- negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: A propensity score matching study based on SEER database
11    52    1
Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer
12    71    0
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
9    90    0
Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer

Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer
8    62    0
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: Characteristics and survival data

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: Characteristics and survival data
7    77    0
Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/ HER2-positive breast cancer

Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/ HER2-positive breast cancer
8    58    0
FOXA1 and AR in invasive breast cancer: New findings on their co-expression and impact on prognosis in ER-positive patients

FOXA1 and AR in invasive breast cancer: New findings on their co-expression and impact on prognosis in ER-positive patients
9    31    1